Skip to main content
OpenTrials

Clinical trial condition

Ovarian Undifferentiated Carcinoma

Explore clinical trials studying Ovarian Undifferentiated Carcinoma. Study availability and eligibility vary by location and protocol.

14 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Ovarian Undifferentiated Carcinoma trial results

Completed

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00951496

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine System Diseases, +55 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
View all 503 locations
View Trial Details
Completed

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

NCT02020707

Conditions
Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, +45 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
View Trial Details
Completed

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

NCT01097746

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +48 more
Locations
  • M D Anderson Cancer Center Houston, Texas, United States
  • MD Anderson Regional Care Center-Katy Houston, Texas, United States
  • MD Anderson Regional Care Center-Bay Area Nassau Bay, Texas, United States
  • MD Anderson Regional Care Center-Sugar Land Sugar Land, Texas, United States
View Trial Details
Completed

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00888615

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +39 more
Locations
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • John Muir Medical Center-Concord Campus Concord, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of California San Diego San Diego, California, United States
View all 163 locations
View Trial Details
Completed

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

NCT00989651

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +59 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of Colorado Hospital Aurora, Colorado, United States
  • Augusta University Medical Center Augusta, Georgia, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
View all 23 locations
View Trial Details
Completed

Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01504126

Conditions
Adnexal Diseases, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Diseases, +44 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Lyndon Baines Johnson General Hospital Houston, Texas, United States
  • M D Anderson Cancer Center Houston, Texas, United States
  • The Woman's Hospital of Texas Houston, Texas, United States
View Trial Details
Completed

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT01489371

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +22 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • University of New Mexico Cancer Center Albuquerque, New Mexico, United States
View Trial Details
Active, Not Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

NCT04092270

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +43 more
Locations
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
View Trial Details
Active, Not Recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02446600

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +27 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
View all 356 locations
View Trial Details

Related conditions